融券方面，春立医疗10月17日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 10月17日，春立医疗涨1.47%，成交额1.08亿元。两融数据显示，当日春立医疗获融资买入额754.25万 元，融资偿还1068.99万元，融资净买入-314.74万元。截至10月17日，春立医疗融资融券余额合计 3134.41万元。 来源：新浪证券-红岸工作室 融资方面 ...

Core Viewpoint - Spring Medical has seen a significant stock price increase of 9.18% over the past three days, indicating strong market interest and potential growth in the orthopedic medical device sector [1] Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [1] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] - The company exports its products to various regions, including Asia, South America, Africa, Oceania, and Europe [1] - The revenue composition is primarily from medical device products (99.89%) with a minor contribution from other sources (0.11%) [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Spring Medical, holding 1.603 million shares, which is 0.42% of the circulating shares [2] - The fund has realized a floating profit of approximately 2.0518 million yuan today and 3.3503 million yuan during the three-day price increase [2] - The fund was established on January 23, 2014, and has a current scale of 2.405 billion yuan, with a year-to-date return of 43.87% [2] Fund Management - The fund manager of Southern Medical Health Flexible Allocation Mixed A is Cai Qiang, who has been in the position for 2 years and 128 days [3] - The total asset size of the fund is 4.213 billion yuan, with the best return during his tenure being 21.06% and the worst being 0% [3]

Core Viewpoint - Spring Medical has shown significant stock price growth this year, with a 99.04% increase, indicating strong market performance and investor interest [2]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, primarily joint prosthetics and spinal implants [2]. - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [2]. - The company exports its products to various regions, including Asia, South America, Africa, Oceania, and Europe [2]. - The revenue composition is heavily weighted towards medical device products, accounting for 99.89% of total revenue [2]. Financial Performance - As of June 30, 2025, Spring Medical reported a revenue of 488 million yuan, representing a year-on-year growth of 28.27% [3]. - The net profit attributable to shareholders for the same period was 114 million yuan, reflecting a year-on-year increase of 44.85% [3]. - Cumulative cash dividends since the A-share listing amount to 359 million yuan, with 309 million yuan distributed over the past three years [4]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders decreased by 17.57% to 5,920, while the average circulating shares per person increased by 341.41% to 48,836 shares [3]. - The stock price increased by 2.13% on October 20, 2023, reaching 25.38 yuan per share, with a total market capitalization of 9.735 billion yuan [1]. - Major shareholders include Ping An Low Carbon Economy Mixed A and Southern Medical Health Flexible Allocation Mixed A, with notable changes in their holdings [4].

证券之星消息，截至2025年10月17日收盘，春立医疗(688236)报收于24.85元，上涨1.47%，换手率 1.53%，成交量4.42万手，成交额1.08亿元。 10月17日的资金流向数据方面，主力资金净流出735.82万元，占总成交额6.83%，游资资金净流出 1067.38万元，占总成交额9.91%，散户资金净流入1803.2万元，占总成交额16.74%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-17 | 24.85 | 1.47% | -735.82万 | -6.83% | -1067.38万 | -9.91% | 1803.20万 | - 16.74% | | 2025-10-16 | 24.49 4.57% | | # 83.60万 | 1.01% | 123.78万 | 1.49% | -207.38万 | -2.49% | | 2025-10-15 | ...

数据显示，南方基金旗下1只基金位居春立医疗十大流通股东。南方医药保健灵活配置混合A （000452）二季度新进十大流通股东，持有股数160.3万股，占流通股的比例为0.42%。根据测算，今日 浮盈赚取约72.14万元。连续3天上涨期间浮盈赚取349.46万元。 南方医药保健灵活配置混合A（000452）成立日期2014年1月23日，最新规模24.05亿。今年以来收益 45.86%，同类排名1147/8160；近一年收益33.46%，同类排名2729/8021；成立以来收益230.72%。 南方医药保健灵活配置混合A（000452）基金经理为王峥娇。 来源：新浪基金∞工作室 10月17日，春立医疗涨1.84%，截至发稿，报24.94元/股，成交1.08亿元，换手率1.53%，总市值95.66亿 元。春立医疗股价已经连续3天上涨，区间累计涨幅9.58%。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业 ...

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Spring Medical (01858.HK), indicating a net increase of 27,700 shares on October 16, 2025, while also noting a cumulative net reduction of 171,100 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Spring Medical on 8 occasions, resulting in a total net reduction of 251,600 shares [1] - As of the latest data, southbound funds hold 42,983,100 shares of Spring Medical, which represents 45.17% of the company's total issued ordinary shares [1] Group 2 - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company's joint prosthetic products cover major human joints such as hip, knee, shoulder, and elbow, while its spinal implant products consist of a full range of spinal fixation systems [2] - Spring Medical exports its products to various countries and regions across Asia, South America, Africa, Oceania, and Europe [2]

Group 1 - The core viewpoint of the news is that Spring Medical experienced a stock price increase of 5.04%, reaching 24.60 CNY per share, with a total market capitalization of 9.436 billion CNY [1] - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [1] - The company's main revenue source is from medical device products, accounting for 99.89% of total revenue, with exports to various regions including Asia, South America, Africa, Oceania, and Europe [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Spring Medical, with its Guolian An Stable Mixed A Fund holding 297,700 shares, representing 3.06% of the fund's net value [2] - The Guolian An Stable Mixed A Fund has achieved a year-to-date return of 27.33% and a one-year return of 28.43%, ranking 3332 out of 8161 and 3393 out of 8021 respectively in its category [2] - The fund manager, Shu Leyan, has been in charge for 2 years and 91 days, with the fund's total assets amounting to 333 million CNY [3]

Core Viewpoint - Spring Medical has shown significant stock performance with an 87.51% increase year-to-date, despite a slight decline in recent trading days [1][2] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [1] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] - Spring Medical exports its products to various regions, including Asia, South America, Africa, Oceania, and Europe [1] Financial Performance - For the first half of 2025, Spring Medical reported a revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 17.57% to 5,920, while the average number of circulating shares per person increased by 341.41% to 48,836 shares [2] - Notable institutional shareholders include Ping An Low Carbon Economy Mixed A and Southern Medical Health Flexible Allocation Mixed A, with the former increasing its holdings by 2.77 million shares [3]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a positive performance with a closing price of 23.42 yuan, reflecting a 2.9% increase on October 15, 2025, despite mixed capital flows [1][2]. Financial Performance - Chunli Medical reported a main revenue of 488 million yuan for the first half of 2025, representing a year-on-year increase of 28.27% [3]. - The net profit attributable to shareholders was 114 million yuan, up 44.85% year-on-year, while the non-recurring net profit reached 106 million yuan, increasing by 61.09% [3]. - In Q2 2025, the company achieved a single-quarter main revenue of 258 million yuan, a significant rise of 62.85% year-on-year, with a net profit of approximately 56.4 million yuan, up 136.7% [3]. Market Position - Chunli Medical's total market capitalization stands at 8.983 billion yuan, which is below the industry average of 11.879 billion yuan, ranking 42 out of 123 in the medical device sector [3]. - The company has a price-to-earnings ratio (P/E) of 39.24, which is lower than the industry average of 67.67, ranking 46 out of 123 [3]. - The gross margin of Chunli Medical is 67.09%, significantly higher than the industry average of 51.85%, ranking 27 out of 123 [3]. Capital Flow Analysis - On October 15, 2025, the net outflow of main funds was 638,400 yuan, accounting for 1.33% of the total transaction amount, while retail funds saw a net outflow of 777,800 yuan, representing 1.62% [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from both institutional and retail investors [2]. Analyst Ratings - In the last 90 days, eight institutions have provided ratings for Chunli Medical, with seven recommending a buy and one suggesting an increase in holdings. The average target price set by these institutions is 30.61 yuan [4].

证券之星消息，截至2025年10月14日收盘，春立医疗(688236)报收于22.76元，下跌0.74%，换手率 0.54%，成交量1.56万手，成交额3581.34万元。 | 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 87.3 乙元 | 117.95亿元 | 43 123 | | 净资产 | 29.09亿元 | 38.89亿元 | 53 123 | | 净利润 | 1.14亿元 | 1.49亿元 | 39 123 | | 市盈率(动) | 38.13 | 66.45 | 45 123 | | 市净率 | 3 | 3.78 | 70 123 | | 毛利率 | 67.09% | 51.85% | 27 123 | | 净利率 | 23.48% | 10.39% | 31 123 | | ROE | 3.98% | 1.8% | 43 123 | 春立医疗2025年中报显示，公司主营收入4.88亿元，同比上升28.27%；归母净利润1.14亿元，同比上升 44.85%；扣非净利润1.06亿元，同比上升61.09%；其中2025 ...